AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 217 filers reported holding AMICUS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.30 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $76 | -77.8% | 6,244 | -77.1% | 0.03% | -81.8% |
| Q2 2023 | $343 | +183.5% | 27,318 | +176.4% | 0.18% | +120.7% |
| Q4 2022 | $121 | -99.6% | 9,882 | +197.8% | 0.08% | +182.8% |
| Q1 2022 | $32,000 | +88.2% | 3,318 | +128.2% | 0.03% | +20.8% |
| Q4 2021 | $17,000 | -63.0% | 1,454 | -52.7% | 0.02% | -54.7% |
| Q3 2021 | $46,000 | -87.0% | 3,072 | -91.6% | 0.05% | -85.1% |
| Q2 2021 | $353,000 | +146.9% | 36,594 | +492.3% | 0.36% | +123.9% |
| Q4 2020 | $143,000 | +240.5% | 6,178 | +107.6% | 0.16% | +278.6% |
| Q3 2020 | $42,000 | -58.8% | 2,976 | -60.4% | 0.04% | +7.7% |
| Q2 2020 | $102,000 | -28.7% | 7,520 | -51.5% | 0.04% | -83.3% |
| Q1 2020 | $143,000 | +28.8% | 15,495 | +36.5% | 0.23% | +82.0% |
| Q4 2019 | $111,000 | +98.2% | 11,348 | +155.1% | 0.13% | +300.0% |
| Q2 2019 | $56,000 | -1.8% | 4,448 | +6.0% | 0.03% | 0.0% |
| Q1 2019 | $57,000 | – | 4,196 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |